APSR2026-137

Yes
Late-Breaking
Submitted
Poster Presentation
 
AP10-001
P01
 
Format: PPTX Only
https://storage.unitedwebnetwork.com/files/1285/1210476-46904-APSR26_Poster_429514.pdf
Format: PDF Only
07. COPD
14

No more than 15 authors can be listed.
Please ensure the authors are listed in the right order.
If there are multiple affiliations, please use the "+" button next to "Select Country/Region" to add additional affiliation fields.

Keitaro Nakamoto * Kyorin University School of Medicine Respiratory Medicine Tokyo Japan
Masato Watanabe - Kyorin University School of Medicine Respiratory Medicine Tokyo Japan
Masaoki Saito - Kyorin University School of Medicine Respiratory Medicine Tokyo Japan
Keisuke Kasuga - Kyorin University School of Medicine Respiratory Medicine Tokyo Japan
Chika Miyaoka - Kyorin University School of Medicine Respiratory Medicine Tokyo Japan
Yuki Yoshida - Kyorin University School of Medicine Respiratory Medicine Tokyo Japan
Hiroki Nunokawa - Kyorin University School of Medicine Respiratory Medicine Tokyo Japan
Junpei Aso - Kyorin University School of Medicine Respiratory Medicine Tokyo Japan
Yasuo Nakamoto - Kyorin University School of Medicine Respiratory Medicine Tokyo Japan
Manabu Ishida - Kyorin University School of Medicine Respiratory Medicine Tokyo Japan
Mitsuru Sada - Kyorin University School of Medicine Respiratory Medicine Tokyo Japan
Saori Takata - Kyorin University School of Medicine Respiratory Medicine Tokyo Japan
Takeshi Saraya - Kyorin University School of Medicine Respiratory Medicine Tokyo Japan
Haruyuki Ishii - Kyorin University School of Medicine Respiratory Medicine Tokyo Japan
 
Presenting Author Details
Keitaro
Nakamoto
keichon2000@yahoo.co.jp
+818040028946
41-50
Japan
Original Research
Serum calprotectin levels in patients with COPD
Maximum 25 words
Abstract Content
Chronic obstructive pulmonary disease (COPD) is characterized by chronic respiratory symptoms and airflow limitation. Calprotectin is known as a marker of disease severity in chronic inflammatory diseases, such as inflammatory bowel disease and rheumatic diseases. However, the relationship between calprotectin and COPD remains unclear. In this study, we investigated the significance of serum calprotectin levels in patients with COPD.
We recruited patients with stable COPD. We examined the characteristics, laboratory findings, and questionnaires. Serum calprotectin levels were measured using enzyme-linked immunosorbent assays (ELISA).
Sixty-four patients (52 men) were included in this study. The median age was 65 years (range, 62–94 years). The severity of airflow limitation was staged according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria as follows: stage 1, 24 patients; stage 2, 31 patients; stage 3, 7 patients; and stage 4, 2 patients. Serum calprotectin levels were correlated with WBC and neutrophil counts, CAT score, and SQRQ score (rs = 0.581, P < 0.001, rs = 0.588, P < 0.001, rs = 0.367, P = 0.003, rs = 0.405, P = 0.001, respectively). Serum calprotectin levels were negatively correlated with %FVC and %FEV1 (rs = -0.253, P = 0.044, rs = -0.256, P = 0.041, respectively). Serum calprotectin levels were significantly higher in the severe airflow limitation group (GOLD 3,4) than in the non-severe group (GOLD 1,2).
Serum calprotectin can be used as a marker of severity and reflects neutrophilic inflammation in COPD.
 
 
 
 
 
No
No
 
JPG or JPEG or PNG format ONLY
 
maximum 3 keywords and no abbreviations, separated by commas
 
242